These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 21787028)
1. Attitudes of Florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances. Fass JA; Hardigan PC J Manag Care Pharm; 2011; 17(6):430-8. PubMed ID: 21787028 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of Florida physicians' knowledge and attitudes toward accessing the state prescription drug monitoring program as a prescribing tool. Gershman JA; Gershman JA; Fass AD; Popovici I Pain Med; 2014 Dec; 15(12):2013-9. PubMed ID: 24931295 [TBL] [Abstract][Full Text] [Related]
3. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use. Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394 [TBL] [Abstract][Full Text] [Related]
4. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions. Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350 [TBL] [Abstract][Full Text] [Related]
5. Using the theory of planned behavior to examine pharmacists' intention to utilize a prescription drug monitoring program database. Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels S; Novak S Res Social Adm Pharm; 2014; 10(2):285-96. PubMed ID: 23816495 [TBL] [Abstract][Full Text] [Related]
6. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study. Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575 [TBL] [Abstract][Full Text] [Related]
7. Examination of psychosocial predictors of Virginia pharmacists' intention to utilize a prescription drug monitoring program using the theory of planned behavior. Gavaza P; Fleming M; Barner JC Res Social Adm Pharm; 2014; 10(2):448-58. PubMed ID: 23953982 [TBL] [Abstract][Full Text] [Related]
8. Educating Pharmacists on a Prescription Drug Monitoring Program. Fleming ML; Phan Y; Ferries EA; Hatfield MD J Pharm Pract; 2016 Dec; 29(6):543-548. PubMed ID: 25947949 [TBL] [Abstract][Full Text] [Related]
9. Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use. Rutkow L; Chang HY; Daubresse M; Webster DW; Stuart EA; Alexander GC JAMA Intern Med; 2015 Oct; 175(10):1642-9. PubMed ID: 26280092 [TBL] [Abstract][Full Text] [Related]
10. Integration of prescription drug monitoring programs (PDMP) in pharmacy practice: Improving clinical decision-making and supporting a pharmacist's professional judgment. Norwood CW; Wright ER Res Social Adm Pharm; 2016; 12(2):257-66. PubMed ID: 26143489 [TBL] [Abstract][Full Text] [Related]
11. Predictors of pharmacists' likelihood to query prescription drug monitoring program databases. Arnold A; Bentley JP; Patel A; Holmes E J Am Pharm Assoc (2003); 2021; 61(5):614-622.e3. PubMed ID: 33994328 [TBL] [Abstract][Full Text] [Related]
12. Prescription Drug Monitoring Programs and Pharmacist Orientation Toward Dispensing Controlled Substances. Fendrich M; Bryan JK; Hooyer K Subst Use Misuse; 2018 Jul; 53(8):1324-1330. PubMed ID: 29297725 [TBL] [Abstract][Full Text] [Related]
13. Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review. Johnston K; Alley L; Novak K; Haverly S; Irwin A; Hartung D J Am Pharm Assoc (2003); 2018; 58(5):568-576. PubMed ID: 30030040 [TBL] [Abstract][Full Text] [Related]
14. Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program. Delcher C; Wagenaar AC; Goldberger BA; Cook RL; Maldonado-Molina MM Drug Alcohol Depend; 2015 May; 150():63-8. PubMed ID: 25746236 [TBL] [Abstract][Full Text] [Related]
15. The Last State to Grant Nurse Practitioners DEA Licensure: An Education Improvement Initiative on the Florida Prescription Drug Monitoring Program. Kellams JR; Maye JP J Addict Nurs; 2017; 28(3):135-142. PubMed ID: 28863055 [TBL] [Abstract][Full Text] [Related]
16. Clinical decision making involving prescription drug monitoring programs: A factorial, vignette-based study among student pharmacists. Tata V; Varisco TJ; Du N; Nguyen J; Haghparast P; Thornton JD J Am Pharm Assoc (2003); 2021; 61(3):316-324. PubMed ID: 33579594 [TBL] [Abstract][Full Text] [Related]
17. Concern about the Expanding Prescription Drug Epidemic: A Survey of Licensed Prescribers and Dispensers. Wright RE; Reed N; Carnes N; Kooreman HE Pain Physician; 2016 Jan; 19(1):E197-208. PubMed ID: 26752487 [TBL] [Abstract][Full Text] [Related]
18. Prescription drug monitoring program design and function: A qualitative analysis. Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492 [TBL] [Abstract][Full Text] [Related]
19. Prescription drug monitoring and dispensing of prescription opioids. Brady JE; Wunsch H; DiMaggio C; Lang BH; Giglio J; Li G Public Health Rep; 2014; 129(2):139-47. PubMed ID: 24587548 [TBL] [Abstract][Full Text] [Related]
20. Prescription drug monitoring programs, a response to doctor shopping: purpose, effectiveness, and directions for future research. Worley J Issues Ment Health Nurs; 2012 May; 33(5):319-28. PubMed ID: 22545639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]